Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

A recent paper published in Nature Medicine sheds light on a remarkable case where Alzheimer's appears to have been medically acquired through the transmission of the amyloid-beta protein. Typically ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

In addition, each group was further subdivided into a metabolic health group and a metabolic syndrome group according to ...